{"id":328912,"date":"2019-02-12T11:14:02","date_gmt":"2019-02-12T11:14:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=328912"},"modified":"2019-02-12T11:14:02","modified_gmt":"2019-02-12T11:14:02","slug":"bioresorbable-vascular-scaffold-market-to-surpass-us-4256-million-by-2026","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bioresorbable-vascular-scaffold-market-to-surpass-us-4256-million-by-2026_328912.html","title":{"rendered":"Bioresorbable Vascular Scaffold Market to Surpass US$ 425.6 Million by 2026"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Bioresorbable Vascular Scaffold Market”<\/div>\n<\/div>\n<\/div>\n
Bioresorbable Vascular Scaffold Market to Surpass US$ 425.6 Million by 2026. Bioresorbable Vascular Scaffold Market is projected to exhibit a CAGR of 12.5% over the forecast period (2018 \u2013 2026)<\/div>\n

Launch of novel bioresorbable vascular scaffold by market players is expected to augment the market growth<\/strong><\/span><\/p>\n

Key players in the market are focused on launching novel bioresorbable vascular scaffold in order to reduce the risk of coronary artery inflammation, which leads to thrombosis and stent restenosis and address critical unmet needs of patients. For instance, in May 2017, Medtronic launched 4.5 mm and 5 mm sizes Resolute Onyx, drug-eluting stent, in U.S. following FDA approval, which was the first drug-eluting stent.<\/span><\/p>\n

Similarly, in September 2012, Abbott launched Absorb, a bioresorbable vascular scaffold disappearing stent, across Europe and parts of Asia Pacific and Latin America. In May 2017 Medtronic, Plc. received U.S. Food and Drug Administration (FDA) approval for its Resolute Onyx, a 2.0mm size zotarolimus-eluting stent with unique continuous sinusoid technology.<\/span><\/p>\n

Request Sample Copy of This Report @ https:\/\/www.coherentmarketinsights.com\/insight\/request-sample\/2471<\/a> <\/strong><\/span><\/p>\n

Global Bioresorbable Vascular Scaffold Market, by Product Type (Synthetic and Biological), by Material (Metal based BVS, Polymer based BVS), by Application (Coronary Artery Stents, Peripheral Artery Stents, and Others), by End User (Hospitals, Ambulatory Surgical Centers, Cardiac Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 147.0 million in 2017, and is projected to exhibit a CAGR of 12.5% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.<\/span><\/p>\n

Browse 22 Market Data Tables and 26 Figures spread through 158 Pages and in-depth TOC on ‘Bioresorbable Vascular Scaffold Market’- Global Forecast to 2026, Product Type (Synthetic, Biological), by Material (Metal based BVS, Polymer Based BVS), by application (Coronary Artery Stents, Peripheral Artery Stents, Others), by End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)<\/span><\/p>\n

To know the latest trends and insights prevalent in the Bioresorbable Vascular Scaffold market, click the link below:<\/strong><\/span><\/p>\n

https:\/\/www.coherentmarketinsights.com\/market-insight\/bioresorbable-vascular-scaffold-market-2471<\/a> <\/strong><\/span><\/p>\n

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance its product portfolio. For instance, in February 2016, Maquet Medical Systems, a Getinge Group Company, announced plans to enter into partnership with BIOTRONIK, a Germany-based manufacturer of cardiovascular and endovascular medical devices, to distribute BIOTRONIK’s peripheral vascular devices in the U.S.<\/span><\/p>\n

Key Takeaways of the Bioresorbable Vascular Scaffold Market:<\/strong><\/span><\/p>\n